Study results demonstrated a high rate of clinical success from a combination of Biomatlante’s MBCP+™ synthetic bone graft plus mesenchymal stem cells (MSCs), particularly in the treatment of long bone non-unions.
The REBORNE 12-center EU clinical trial sought to establish feasibility, relevance and efficacy of the association of MBCP+ (Macroporous Biphasic Calcium Phosphate) with MSCs.
The trial is now extended to attempt to provide the same level of clinical performance at an affordable price by combining the MBCP technology with autologous concentrated bone marrow aspirate. Clinical trials are slated to begin in coming months.
In 3Q15, Biomatlante received CE Mark approval for strip and plug formats of EZ CURE™, a combination of highly-purified collagen Type I based on MBCP technology.
Study results demonstrated a high rate of clinical success from a combination of Biomatlante's MBCP+™ synthetic bone graft plus mesenchymal stem cells (MSCs), particularly in the treatment of long bone non-unions.
The REBORNE 12-center EU clinical trial sought to establish feasibility, relevance and efficacy of the association of...
Study results demonstrated a high rate of clinical success from a combination of Biomatlante’s MBCP+™ synthetic bone graft plus mesenchymal stem cells (MSCs), particularly in the treatment of long bone non-unions.
The REBORNE 12-center EU clinical trial sought to establish feasibility, relevance and efficacy of the association of MBCP+ (Macroporous Biphasic Calcium Phosphate) with MSCs.
The trial is now extended to attempt to provide the same level of clinical performance at an affordable price by combining the MBCP technology with autologous concentrated bone marrow aspirate. Clinical trials are slated to begin in coming months.
In 3Q15, Biomatlante received CE Mark approval for strip and plug formats of EZ CURE™, a combination of highly-purified collagen Type I based on MBCP technology.
Copy to clipboard 
